Sign in
Farzin

Farzin

Senior Vice President and Biotechnology Equity Research Analyst at Jefferies Financial Group Inc.

New York, NY, US

Farzin Haque is a Senior Vice President and Biotechnology Equity Research Analyst at Jefferies, specializing in biotechnology sector analysis with a focus on companies such as Allakos and Vera. He covers several biopharmaceutical stocks, and his track record includes a 20% success rate and an average return of -40.8% on recommendations, according to platforms like TipRanks. Haque has held his SVP role at Jefferies in recent years, with no publicly documented previous employments found in search results. He holds significant sector expertise, but specific securities licenses or FINRA credentials are not publicly listed.

Farzin's questions to Travere Therapeutics (TVTX) leadership

Question · Q3 2024

Farzin, on behalf of Maurie Raycroft at Jefferies, asked if data from the open-label extension would be included in the FSGS Type C meeting package and whether pre-specified analyses are considered sufficient or if more post-hoc work is needed.

Answer

SVP of Research and Development Dr. Bill Rote confirmed that open-label extension data from both the DUET and DUPLEX studies will be included. He stated they will present existing pre-specified analyses and will work with the FDA to align on any additional analyses required for the submission, rather than conducting extensive new post-hoc analyses beforehand.

Ask follow-up questions

Fintool

Fintool can predict Travere Therapeutics logo TVTX's earnings beat/miss a week before the call

Let Fintool AI Agent track Farzin for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free